Skip to main content
Publish date:

Cellceutix Investors See Red Flags in Drug Study

Does Cellceutix have something to hide?

Cellceutix'  (CTIX) CEO Leo Ehrlich recently railed against Mako Research for negative articles written about his company.  TheStreet'sAdam Feuerstein says the rant may have been a smokescreen to divert attention from the company's actual problems. Feuerstein believes the data the company reported concerning the Phase 2 study of its Prurisol drug were exaggerated and the company withheld important negative data from investors.

This article was written by a staff member of TheStreet.

TheStreet Recommends